logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5662.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5662.produseast1
Showing 1 - 3 of 3 Items
Showing 1 - 3 of 3 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Characteristics of children and adolescents with multidrug-resistant and rifampicin-resistant tuberculosis and their association with treatment outcomes: a systematic review and individual participant data meta-analysis

Garcia-Prats AJ, Garcia-Cremades M, Cox V, Kredo T, Dunbar R,  et al.
2025-02-01 • Lancet Child and Adolescent Health
2025-02-01 • Lancet Child and Adolescent Health

BACKGROUND

There are few data on the treatment of children and adolescents with multidrug-resistant (MDR) or rifampicin-resistant (RR) tuberculosis, especially ...

Journal Article
|
Research
Journal Article
|
Research

Lamivudine monotherapy as a holding regimen for HIV-positive children

Patten GE, Bernheimer J, Fairlie L, Rabie H, Sawry S,  et al.
2018-10-11 • PLOS One
2018-10-11 • PLOS One
BACKGROUND:
In resource-limited settings holding regimens, such as lamivudine monotherapy (LM), are used to manage HIV-positive children failing combination antiretroviral therapy (...

Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis

Harausz EP, Garcia-Prats AJ, Law S, Schaaf HS, Kredo T,  et al.
2018-07-11 • PLOS Medicine
2018-07-11 • PLOS Medicine
An estimated 32,000 children develop multidrug-resistant tuberculosis (MDR-TB; Mycobacterium tuberculosis resistant to isoniazid and rifampin) each year. Little is known about the optima...